61. |
62. Poročilo o preskusu št.: LVG 2024-053 : vzorec št. 2024/00116Tine Hauptman, Zina Devetak, Špela Hočevar, Barbara Piškur, 2024, expertise, arbitration decision Keywords: varstvo gozdov, morfološke analize, Geosmithia morbida, bolezen tisočerih rakov, vektorji, rtPCR
Published in DiRROS: 19.06.2024; Views: 114; Downloads: 0
This document has many files! More... |
63. |
64. Poročilo o preskusu št.: LVG 2024-051 : vzorec št. 2024/00087Tine Hauptman, Špela Hočevar, Barbara Piškur, 2024, expertise, arbitration decision Keywords: varstvo gozdov, morfološke analize, Euwallacea fornicatus, Neocosmospora euwallaceae, strokovne naloge IVHVVR, molekularne analize
Published in DiRROS: 19.06.2024; Views: 110; Downloads: 2
This document has many files! More... |
65. Poročilo o preskusu št.: LVG 2024-049 : vzorec št. 2024/00114Tine Hauptman, Zina Devetak, Špela Hočevar, Barbara Piškur, 2024, expertise, arbitration decision Keywords: varstvo gozdov, morfološke analize, hrošči, ličinke, hlodovina, molekularne analize, strokovne naloge IVHVVR
Published in DiRROS: 19.06.2024; Views: 111; Downloads: 0
This document has many files! More... |
66. Poročilo o preskusu št.: LVG 2024-048 : vzorec št. 2024/00122Tine Hauptman, Špela Hočevar, Barbara Piškur, 2024, expertise, arbitration decision Keywords: varstvo gozdov, morfološke analize, Fusarium circinatum, Pinus, borov smolasti rak, rtPCR
Published in DiRROS: 19.06.2024; Views: 109; Downloads: 0
This document has many files! More... |
67. |
68. |
69. Kinetics of surface wettability of aromatic polymers (PET, PS, PEEK, and PPS) upon treatment with neutral oxygen atoms from non-equilibrium oxygen plasmaAlenka Vesel, Rok Zaplotnik, Gregor Primc, Miran Mozetič, 2024, original scientific article Abstract: The wettability of polymers is usually inadequate to ensure the appropriate spreading of polar liquids and thus enable the required adhesion of coatings. A standard ecologically benign method for increasing the polymer wettability is a brief treatment with a non-equilibrium plasma rich in reactive oxygen species and predominantly neutral oxygen atoms in the ground electronic state. The evolution of the surface wettability of selected aromatic polymers was investigated by water droplet contact angles deposited immediately after exposing polymer samples to fluxes of oxygen atoms between 3 × 1020 and 1 × 1023 m−2 s −1 . The treatment time varied between 0.01 and 1000 s. The wettability evolution versus the O-atom fluence for all aromatic polymers followed similar behavior regardless of the flux of O atoms or the type of polymer. In the range of fluences between approximately 5 × 1020 and 5 × 1023 m−2 , the water contact angle decreased exponentially with increasing fluence and dropped to 1/e of the initial value after receiving the fluence close to 5 × 1022 m−2
Published in DiRROS: 19.06.2024; Views: 91; Downloads: 31
 Full text (3,48 MB) |
70. Mobocertinib in patients with EGFR exon 20 insertion-positive non-small cell lung cancer (MOON) : an international real-world safety and efficacy analysisOliver Illini, Felix Carl Saalfeld, Petros Christopoulos, Michaël Duruisseaux, Anders Vikström, Nir Peled, Ingel Demedts, Elizabeth Dudnik, Anna Eisert, Urška Janžič, Katja Mohorčič, Marija Ivanović, Sayed M. S. Hashemi, 2024, original scientific article Abstract: EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional EGFR tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed to target EGFR Ex20. We performed an international, real-world safety and efficacy analysis on patients with EGFR Ex20-positive NSCLC enrolled in a mobocertinib early access program. We explored the mechanisms of resistance by analyzing postprogression biopsies, as well as cross-resistance to amivantamab. Data from 86 patients with a median age of 67 years and a median of two prior lines of treatment were analyzed. Treatment-related adverse events (TRAEs) occurred in 95% of patients. Grade ≥3 TRAEs were reported in 38% of patients and included diarrhea (22%) and rash (8%). In 17% of patients, therapy was permanently discontinued, and two patients died due to TRAEs. Women were seven times more likely to discontinue treatment than men. In the overall cohort, the objective response rate to mobocertinib was 34% (95% CI, 24–45). The response rate in treatment-naïve patients was 27% (95% CI, 8–58). The median progression-free and overall survival was 5 months (95% CI, 3.5–6.5) and 12 months (95% CI, 6.8–17.2), respectively. The intracranial response rate was limited (13%), and one-third of disease progression cases involved the brain. Mobocertinib also showed antitumor activity following EGFR Ex20-specific therapy and vice versa. Potential mechanisms of resistance to mobocertinib included amplifications in MET, PIK3CA, and NRAS. Mobocertinib demonstrated meaningful efficacy in a real-world setting but was associated with considerable gastrointestinal and cutaneous toxicity.
Keywords: medicina, non-small cell lung cancer, EGFR exon 20 inhibitors, mobocertinib, real-world data, exon 20 insertion
Published in DiRROS: 19.06.2024; Views: 94; Downloads: 31
Full text (1,93 MB)
This document has many files! More... |
